Seojin Park, PharmD, MS

Gilead Sciences, Inc.

Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-473) Health Care Resource Use Burden Among People With HIV (PWH) and Concurrent Mental Health Disorders (MHDs): Claims Analysis of Treatment-Naïve Medicaid Population Initiating Multi-Tablet Regimens (MTRs) vs. Single-Table Regimens (STRs)
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-474) Effects of Antiretroviral Resistance on Outcomes and Healthcare Resource Use of People with HIV in the United States and Europe – A Real-World Survey
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-512) Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre‑exposure Prophylaxis (PrEP): A Real-World Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT